Pharmaceuticals

Protein Degradation Therapy Market Expected To Grow Steadily And Approach $4.1 Billion By 2030

May 4, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Expansion In Market Value Is Forecasted For The Protein Degradation Therapy Market Between 2026 And 2030?

The protein degradation therapy market size has demonstrated significant expansion in recent years. This market is set to expand from $1.25 billion in 2025 to $1.35 billion in 2026, progressing at a compound annual growth rate (CAGR) of 8.1%. Factors contributing to this historical growth include advancements in molecular biology research, the widening scope of targeted cancer therapies, a deeper understanding of protein dysfunction in illnesses, initial successes in clinical trials, and an increase in venture capital funding for biotechnology.

The protein degradation therapy market is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach $1.83 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.8%. Factors contributing to this growth during the projected timeframe include a rising demand for new cancer treatments, increasing financial commitments to precision oncology, the broadening of protein degradation platforms, heightened clinical trial engagement, and enhanced regulatory backing for pioneering therapeutics. Key trends expected over the forecast period encompass the accelerated development of targeted protein degraders, a greater emphasis on oncology applications, increased capital flowing into protac-based therapies, an expanding pipeline of clinical candidates, and strengthened partnerships between pharmaceutical and biotechnology companies.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20603&type=smp

What Key Drivers Are Fueling The Growth Of The Protein Degradation Therapy Market?

The protein degradation therapy market is anticipated to grow due to the increasing global burden of cancer. Cancer refers to a collection of diseases characterized by the uncontrolled growth and spread of abnormal cells within the body. The rise in cancer rates is largely attributed to a combination of factors, notably the aging population, which is a significant contributor. Additionally, lifestyle elements such as smoking, unhealthy diets, insufficient physical activity, and escalating obesity rates have heightened the risk of various cancers. Protein degradation therapy is essential for cancer treatment because it specifically targets and eliminates proteins that promote cancer growth and survival, potentially overcoming resistance to existing treatments. For instance, in February 2024, a report published by the World Health Organization, a Switzerland-based intergovernmental organization, projected that over 35 million new cancer cases are expected by 2050, representing a 77% increase from the estimated 20 million cases in 2022. Moreover, high human development index (HDI) countries are forecast to experience the largest absolute increase, with an additional 4.8 million new cases predicted in 2050 compared with 2022 estimates. Therefore, the growing incidence of cancer is a key driver for the protein degradation therapy market’s expansion.

Which Segments Define The Protein Degradation Therapy Market Segment Structure?

The protein degradation therapy market covered in this report is segmented –

1) By Type: Bavdegalutamide (ARV – 110), Vepdegestrant (ARV – 471)

2) By Application: Oncology, Neurodegenerative Diseases, Infectious Diseases, Other Applications

3) By End-User: Pharmaceutical Companies, Biotechnology Companies, Academic And Research Institutes

Subsegments:

1) By Bavdegalutamide (ARV-110): Androgen Receptor Degraders, Prostate Cancer Therapy

2) By Vepdegestrant (ARV-471): Estrogen Receptor Degraders, Breast Cancer Therapy

What Trends Are Affecting The Direction Of The Protein Degradation Therapy Market?

Leading companies within the protein degradation therapy market are adopting a strategic partnership approach to cultivate advanced therapies, leverage diverse expertise, pool resources, and accelerate the identification and progression of new drug candidates aimed at disease-causing proteins. These collaborations involve firms utilizing each other’s strengths and assets to achieve reciprocal benefits and collective success. For example, in February 2024, Arvinas, a U.S.-based biotechnology company, unveiled its initial oral PROTAC degrader, ARV-102, engineered to traverse the blood-brain barrier and specifically target LRRK2 for applications in neurodegenerative diseases. The ARV-102 molecule possesses oral bioavailability, a brain-penetrant characteristic, and strong specificity for LRRK2. This innovation enhances company pipelines by addressing targets previously considered undruggable, yet challenges persist regarding long-term safety, manufacturing complexities, and pharmacokinetic optimization given its larger molecular structure.

Who Are The Established Players Within The Protein Degradation Therapy Market?

Major companies operating in the protein degradation therapy market are Relay Therapeutics, Arvinas Holding Company LLC, Kymera Therapeutics, Nurix Therapeutics, Vividion Therapeutics, Mission Therapeutics Ltd., C4 Therapeutics Inc., Cullgen Inc., Frontier Medicines, Foghorn Therapeutics, Aileron Therapeutics, Ribometrix Inc., Nimbus Therapeutics, Jnana Therapeutics, KSQ Therapeutics, Stoke Therapeutics, Flare Therapeutics, Accent Therapeutics, Monte Rosa Therapeutics, Lycia Therapeutics, Dialectic Therapeutics, Amphista Therapeutics, Biotheryx Inc., Cedilla Therapeutics, Dewpoint Therapeutics Inc

Get The Full Protein Degradation Therapy Market Report:

https://www.thebusinessresearchcompany.com/report/protein-degradation-therapy-global-market-report

Which Region Holds The Highest Market Share In The Protein Degradation Therapy Market?

North America was the largest region in the protein degradation therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the protein degradation therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Protein Degradation Therapy Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/protein-degradation-therapy-global-market-report

Browse Through More Reports Similar to the Global Protein Degradation Therapy Market 2026, By The Business Research Company

Home Infusion Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/home-infusion-therapy-global-market-report

Car T Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/car-t-therapy-global-market-report

Aromatherapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/aromatherapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795